Embolization

Information

  • Patent Grant
  • 8173176
  • Patent Number
    8,173,176
  • Date Filed
    Tuesday, March 30, 2004
    20 years ago
  • Date Issued
    Tuesday, May 8, 2012
    12 years ago
Abstract
Embolization, as well as related particles, compositions and methods, are disclosed.
Description
TECHNICAL FIELD

The invention relates to embolization, as well as related particles, compositions and methods.


BACKGROUND

Therapeutic vascular occlusions (embolizations) are used to prevent or treat pathological conditions in situ. Compositions including embolic particles are used for occluding vessels in a variety of medical applications. Delivery of embolic particles through a catheter is dependent on size uniformity, density and compressibility of the embolic particles.


SUMMARY

The invention relates to embolization, as well as related particles, compositions and methods.


In one aspect, the invention features a substantially spherical porous silica particle having a diameter of from about 100 microns to about 3000 microns.


In another aspect, the invention features a composition that includes a carrier fluid that contains a plurality of substantially spherical porous silica particles. At least some of the plurality of substantially spherical silica particles have a diameter of from about 100 microns to about 3000 microns; and


In a further aspect, the invention features a method that includes administering to a subject a therapeutically effective amount of a composition including a plurality of substantially spherical silica particles in a carrier fluid. At least some of the plurality of substantially spherical silica particles having a diameter of from about 100 microns to about 3000 microns.


Embodiments can include one or more of the following.


In some embodiments, the carrier fluid includes a saline solution.


In certain embodiments, the carrier fluid includes a contrast agent.


In some embodiments, at least some of the substantially spherical porous silica particles have a diameter of at most about 1500 microns.


In certain embodiments, for at least some of the substantially spherical porous silica particles, pores in the substantially spherical porous silica particles have a diameter of from about 20 nanometers to about 90 nanometers.


In some embodiments, for at least some of the substantially spherical porous silica particles, a pore volume of the substantially spherical silica particles is from about 0.4 ml/g to about 1.6 ml/g.


In certain embodiments, the particles can have a pore volume distribution such that about 70% or more of the pore volume of the particles is made up of pores having pore diameters which have a tolerance of about 10 nm or less on the mean pore diameter.


In some embodiments, the particles exhibit a loss of attrition resistance of about 0.1% by weight or less.


In certain embodiments, at least some of the plurality of substantially spherical porous silica particles include one or more therapeutic agents, one or more ferromagnetic materials, one or more MRI visible materials and/or one or more radiopaque materials.


In some embodiments, the plurality of substantially spherical porous silica particles are sterilized.


In some embodiments, the composition is administered to the subject by percutaneous injection.


In certain embodiments, the composition is administered to the subject by a catheter.


In some embodiments, the composition is used to treat a cancer condition. The cancer condition can be, for example, ovarian cancer, colorectal cancer, thyroid cancer, gastrointestinal cancer, breast cancer, prostate cancer and/or lung cancer. Treating the cancer condition can include at least partially occluding a lumen in the subject that provides nutrients to a site of the cancer condition with at least some of the plurality of particles.


In certain embodiments, the method includes at least partially occluding a lumen in the subject with at least some of a plurality of particles.


Embodiments may include one or more of the following advantages.


In some embodiments, the silica particles can be substantially biologically inert and non-degradable in the body.


In certain embodiments, the particles can have, and can maintain after implantation, a highly uniform diameter, geometry, pore volume, and pore size.


In general, the particle diameter, geometry, pore volume and pore diameter can be selected based on a desired application. As an example, in some embodiments (e.g., for embolic applications), the particles may have a spherical geometry with a particle diameter of about 3000 microns or less (e.g., about 1500 microns or less) and a relatively large pore volume, to enhance the suspendability of the particles in a delivery medium such as a contrast agent, and a relatively small pore size to enhance surface uniformity, robustness and abrasion resistance. As another example, in certain embodiments (e.g., for a therapeutic agent delivery applications), pore volume can be selected to contain a desired therapeutic agent volume, and pore size can be selected to produce a desired time release, based on diffusion of therapeutic agent from the pores.


In some embodiments, the particles can be made targetable by incorporation of a magnetic material.


In certain embodiments, the particles can be highly incompressible and exhibit a high crushing strength such that they can withstand contact and delivery through a syringe, catheter or the like, as well as, withstand internal body fluid pressure without fracturing.


Features and advantages are in the description, drawings, and claims.





DESCRIPTION OF DRAWINGS


FIG. 1A is a schematic illustrating uterine artery embolization.



FIG. 1B is a greatly enlarged view of region A of FIG. 1A.



FIG. 2 is a cross-sectional view of a silica embolic particle.



FIG. 3 is a flow diagram of a method of making silica embolic particles.





Like reference symbols in the various drawings indicate like elements.


DETAILED DESCRIPTION

Referring to FIGS. 1A and 1B, an embolic composition, including embolic particles 111 and a carrier fluid, is injected into a vessel through an instrument such as a catheter 150. Catheter 150 is connected to a syringe barrel 110 with a plunger 160. Catheter 150 is inserted, for example, into a femoral artery 120 of a subject. Catheter 150 delivers the embolic composition to, for example, occlude a uterine artery 130 leading to a fibroid 140. Fibroid 140 is located in the uterus of a female subject. The embolic composition is initially loaded into syringe 110. Plunger 160 of syringe 110 is then compressed to deliver the embolic composition through catheter 150 into a lumen 165 of uterine artery 130.



FIG. 1B, which is an enlarged view of section 1B of FIG. 1A, shows a uterine artery 130 that is subdivided into smaller uterine vessels 170 (e.g., having a diameter of about two millimeters or less) which feed fibroid 140. The embolic particles 111 in the embolic composition partially or totally fill the lumen of uterine artery 130, either partially or completely occluding the lumen of the uterine artery 130 that feeds uterine fibroid 140.


In general, embolic compositions can be used in, for example, neural, pulmonary, and/or AAA (abdominal aortic aneurysm) applications. The compositions can be used in the treatment of, for example, fibroids, tumors, internal bleeding, arteriovenous malformations (AVMs), and/or hypervascular tumors. The compositions can be used as, for example, fillers for aneurysm sacs, AAA sac (Type II endoleaks), endoleak sealants, arterial sealants, and/or puncture sealants, and/or can be used to provide occlusion of other lumens such as fallopian tubes. Fibroids can include uterine fibroids which grow within the uterine wall (intramural type), on the outside of the uterus (subserosal type), inside the uterine cavity (submucosal type), between the layers of broad ligament supporting the uterus (interligamentous type), attached to another organ (parasitic type), or on a mushroom-like stalk (pedunculated type). Internal bleeding includes gastrointestinal, urinary, renal and varicose bleeding. AVMs are for example, abnormal collections of blood vessels, e.g. in the brain, which shunt blood from a high pressure artery to a low pressure vein, resulting in hypoxia and malnutrition of those regions from which the blood is diverted. In some embodiments, a composition containing the particles can be used to prophylactically treat a condition.


The magnitude of a dose of an embolic composition can vary based on the nature, location and severity of the condition to be treated, as well as the route of administration. A physician treating the condition, disease or disorder can determine an effective amount of embolic composition. An effective amount of embolic composition refers to the amount sufficient to result in amelioration of symptoms or a prolongation of survival of the subject. The embolic compositions can be administered as pharmaceutically acceptable compositions to a subject in any therapeutically acceptable dosage, including those administered to a subject intravenously, subcutaneously, percutaneously, intratrachealy, intramuscularly, intramucosaly, intracutaneously, intra-articularly, orally or parenterally.


An embolic composition can be prepared in calibrated concentrations of the particles for ease of delivery by the physician. Suspensions of the particles in saline solution can be prepared to remain stable (e.g., to not precipitate) over a duration of time. A suspension of the particles can be stable, for example, for from about one minute to about 20 minutes (e.g. from about one minute to about ten minutes, from about two minutes to about seven minutes, from about three minutes to about six minutes). The concentration of particles can be determined by adjusting the weight ratio of the particles to the physiological solution. If the weight ratio of the particles is too small, then too much liquid could be injected into a blood vessel, possibly allowing the particles to stray into lateral vessels. In some embodiments, the physiological solution can contain from about 0.01 weight percent to about 15 weight percent of the particles. A composition can include a mixture of particles, such as particles including one type of surface preferential material and particles including another, different, type of surface preferential material.


In some embodiments, among the particles delivered to a subject in an embolic composition, the majority (e.g., about 50 percent or more, about 60 percent or more, about 70 percent or more, about 80 percent or more, about 90 percent or more) of the particles have a diameter of about 3,000 microns or less (e.g., about 2,500 microns or less; about 2,000 microns or less; about 1,500 microns or less; about 1,200 microns or less; about 900 microns or less; about 700 microns or less; about 500 microns or less; about 400 microns or less; about 300 microns or less; about 100 microns or less) and/or about ten microns or more (e.g., about 100 microns or more; about 300 microns or more; about 400 microns or more; about 500 microns or more; about 700 microns or more; about 900 microns or more; about 1,200 microns or more; about 1,500 microns or more; about 2,000 microns or more; about 2,500 microns or more).


In certain embodiments, the particles delivered to a subject in an embolic composition have a mean diameter of about 3,000 microns or less (e.g., about 2,500 microns or less; about 2,000 microns or less; about 1,500 microns or less; about 1,200 microns or less; about 900 microns or less; about 700 microns or less; about 500 microns or less; about 400 microns or less; about 300 microns or less; about 100 microns or less) and/or about ten microns or more (e.g., about 100 microns or more; about 300 microns or more; about 400 microns or more; about 500 microns or more; about 700 microns or more; about 900 microns or more; about 1,200 microns or more; about 1,500 microns or more; about 2,000 microns or more; about 2,500 microns or more). Exemplary ranges for the mean diameter of particles delivered to a subject include from about 100 microns to about 500 microns; from about 100 microns to about 300 microns; from about 300 microns to about 500 microns; from about 500 microns to about 700 microns; and from about 900 microns to about 1,200 microns. In general, the particles delivered to a subject in an embolic composition have a mean diameter in approximately the middle of the range of the diameters of the individual particles, and a variance of about 20 percent or less (e.g. about 15 percent or less, about ten percent or less).


In some embodiments, the mean size of the particles delivered to a subject in an embolic composition can vary depending upon the particular condition to be treated. As an example, in embodiments in which the particles in an embolic composition are used to treat a liver tumor, the particles delivered to the subject can have a mean diameter of about 500 microns or less (e.g., from about 100 microns to about 300 microns; from about 300 microns to about 500 microns). As another example, in embodiments in which the particles in an embolic composition are used to treat a uterine fibroid, the particles delivered to the subject in an embolic composition can have a mean diameter of about 1,200 microns or less (e.g., from about 500 microns to about 700 microns; from about 700 microns to about 900 microns; from about 900 microns to about 1,200 microns).



FIG. 2 shows a cross-section of a silica particle 111 having pores 112.


In general, particle 111 is substantially spherical. For example, in some embodiments, particle 111 can have a sphericity of about 0.8 or more (e.g., about 0.85 or more, about 0.9 or more, about 0.95 or more, about 0.97 or more). The sphericity of a particle can be determined using a Beckman Coulter RapidVUE Image Analyzer version 2.06 (Beckman Coulter, Miami, Fla.). Briefly, the RapidVUE takes an image of continuous-tone (gray-scale) form and converts it to a digital form through the process of sampling and quantization. The system software identifies and measures particles in an image in the form of a fiber, rod or sphere. The sphericity of a particle, which is computed as Da/Dp (where Da=√(4A/π); Dp=P/π; A=pixel area; P=pixel perimeter), is a value from zero to one, with one representing a perfect circle.


In certain embodiments, particle 111 has a diameter of about 3,000 microns or less (e.g., about 2,500 microns or less; about 2,000 microns or less; about 1,500 microns or less; about 1,200 microns or less; about 900 microns or less; about 700 microns or less; about 500 microns or less; about 400 microns or less; about 300 microns or less; about 100 microns or less) and/or about ten microns or more (e.g., about 100 microns or more; about 300 microns or more; about 400 microns or more; about 500 microns or more; about 700 microns or more; about 900 microns or more; about 1,200 microns or more; about 1,500 microns or more; about 2,000 microns or more; about 2,500 microns or more). Exemplary ranges for the diameter of particle 111 include from about 100 microns to about 500 microns; from about 100 microns to about 300 microns; from about 300 microns to about 500 microns; from about 500 microns to about 700 microns; and from about 900 microns to about 1,200 microns.


In some embodiments, particle 111 has a substantially uniform pore structure. In certain embodiments, particle 111 has non-uniform pore structure.


In certain embodiments, pores 112 can interconnect throughout particle 111. In some embodiments, pores 112 do not interconnect throughout particle 111.


In some embodiments, the diameters of pores 112 in particle 111 are about 20 nanometers or more (e.g., about 30 nanometers or more, about 40 nanometers or more) and/or about 90 nanometers or less (e.g., about 80 nanometers or less, about 70 nanometers or less, about 60 nanometers or less).


In general, the density of particle 111 (e.g., as measured in grams of material per unit volume) is such that it can be readily suspended in a carrier fluid (e.g., a pharmaceutically acceptable carrier, such as a saline solution, a contrast solution, or a mixture thereof) and remain suspended during delivery (e.g., to form a composition, such as an embolization composition). In some embodiments, the density of particle 111 is from about 1.1 grams per cubic centimeter to about 1.4 grams per cubic centimeter. As an example, for suspension in a saline-contrast solution, the density of particle 111 can be from about 1.2 grams per cubic centimeter to about 1.3 grams per cubic centimeter.


In some embodiments, particle 111 can have a high pore diameter and/or a high pore volume uniformity. For example, particle 111 can have a pore diameter distribution such that about 70% or more of the pore volume is made up pores having pore diameters which have a tolerance of not more than 10 nanometers on the mean pore diameter. Pore volume and diameter can be measured by mercury porosimetry.


In certain embodiments, particle 111 can exhibit good resistance to abrasion. For example, a particle can exhibit no detectable loss in attrition resistance. In some embodiments, the loss of attrition of particle 111, as measured using a standard attrition test according to the Peter Spence method, is about 0.1 weight percent or less (e.g., about 0.05 weight percent or less).


In some embodiments, particle 111 can exhibit high crush strength.


Characterization of silica particles is disclosed, for example, in U.S. Pat. No. 4,640,807 and European Patent No. 067459, both of which are hereby incorporated by reference.


In some embodiments, particle 111 can include one or more therapeutic agents (e.g., drugs). The therapeutic agent can be in and/or on particle 111. For example, pores 112 of particle 111 can include a therapeutic agent.


Therapeutic agents include agents that are negatively charged, positively charged, amphoteric, or neutral. Therapeutic agents can be, for example, materials that are biologically active to treat physiological conditions; pharmaceutically active compounds; gene therapies; nucleic acids with and without carrier vectors; oligonucleotides; gene/vector systems; DNA chimeras; compacting agents (e.g., DNA compacting agents); viruses; polymers; hyaluronic acid; proteins (e.g., enzymes such as ribozymes); cells (of human origin, from an animal source, or genetically engineered); stem cells; immunologic species; nonsteroidal anti-inflammatory medications; oral contraceptives; progestins; gonadotrophin-releasing hormone agonists; chemotherapeutic agents; and radioactive species (e.g., radioisotopes, radioactive molecules). Non-limiting examples of therapeutic agents include anti-thrombogenic agents; antioxidants; angiogenic and anti-angiogenic agents and factors; anti-proliferative agents (e.g., agents capable of blocking smooth muscle cell proliferation); anti-inflammatory agents; calcium entry blockers; antineoplastic/antiproliferative/anti-mitotic agents (e.g., paclitaxel, doxorubicin, cisplatin); antimicrobials; anesthetic agents; anti-coagulants; vascular cell growth promoters; vascular cell growth inhibitors; cholesterol-lowering agents; vasodilating agents; agents which interfere with endogenous vasoactive mechanisms; and survival genes which protect against cell death. Therapeutic agents are described, for example, in co-pending U.S. patent application Ser. No. 10/615,276, filed on Jul. 8, 2003, and entitled “Agent Delivery Particle”, which is incorporated herein by reference.


Referring to FIG. 3, particles 111 can be prepared by adaptation of processes described in U.S. Pat. No. 4,640,807 and European Patent No. 067459. In step 300, a silica hydrosol mix is prepared by thorough mixing of an alkali metal silicate and an acid. Next, in step 310, the silica hydrosol is converted to hydrogel particles by dropping the hydrosol mix through a water-immiscible liquid into an aqueous solution. Controlling the break-up of the hydrosol stream enables control of size (e.g., diameter) and shape of the resulting particles. Next, in step 320, the hydrogel particles are partially dried in humid air with temperatures, for example, above 100° C., wherein a controlled amount of water is removed from the particles. The amount of water removed from the particles can be varied, enabling control of the pore volume of the resulting particles. Further, partial drying can reduce (e.g., prevent) formation of cracks resulting in increased crushing strength. A high crushing strength can enable particles 111 to withstand contact and delivery through a syringe, catheter, or the like, as well as, withstand internal body fluid pressure without fracturing. Partial drying in the presence of humid air can yield particles with a narrow distribution of size (i.e., diameter of particles). Next, in step 330, the particles are subjected to hydrothermal treatment (a treatment at elevated temperatures with liquid water and/or water vapor). The hydrothermal treatment yields particles with a narrow distribution of pore diameter. Next, in step 340, the cation content of the hydrogel particles is lowered by removing alkali metals. Finally, in step 350, the particles are dried, at temperatures, for example, about 200° C., and optionally calcined. The particles can be sterilized by e.g., heat or radiation treatment, and suspended in a suitable carrier, e.g., saline and/or a contrast solution such as, Omnipaque 300 (Nycomed, Buckinghamshire, UK. Omnipaque is an aqueous solution of Iohexol, N,N-Bis(2,3-dihydroxypropyl)-T-[N-(2,3-dihydroxypropyl)-acetamide]-2,4,6-trilodo-isophthalamide; Omnipaque 300 contains 647 mg of iohexol equivalent to 300 mg of organic iodine per ml).


The particle diameter, pore diameter and volume and/or uniformity can be controlled to produce particles optimized for a particular application. For example, for a therapeutic delivery application, particle diameter and pore volume can be selected to contain a desired amount of therapeutic agent. The pore diameter can be selected to elute the therapeutic agent into the body based on diffusion processes at a desired rate. A composition including a mixture of particles having known percentages of particles with different particle diameters, pore diameter and pore volume can be prepared to produce a desired dosage profile. Particles of different diameters and pore characteristics can also include different therapeutic agents. The therapeutic agent delivery particles can be implanted into a lumen, e.g., a vascular lumen by catheterization, e.g., as embolic particles, or injected into soft tissue adjacent a cancerous tumor or other lesion.


While certain embodiments have been described, the invention is not so limited.


As an example, in some embodiments a particle can be coated (e.g., with a bioabsorbable material, such as sodium alginate). The coating can contain, for example, one or more therapeutic agents. In some cases, the coating can be, for example, a degradable and/or bioabsorbable polymer which erodes when the particle is administered. The coating can assist in controlling the rate at which therapeutic agent is released from the particle (e.g., from the surface preferential material). For example, the coating can be in the form of a porous membrane. The coating can delay an initial burst of therapeutic agent release. The coating can be applied by dipping or spraying the particle. The erodible polymer can be a polysaccharide (such as an alginate) or a polysaccharide derivative. In some embodiments, the coating can be an inorganic, ionic salt. Other erodible coatings include water soluble polymers (such as polyvinyl alcohol, e.g., that has not been cross-linked), biodegradable poly DL-lactide-poly ethylene glycol (PELA), hydrogels (e.g., polyacrylic acid, haluronic acid, gelatin, carboxymethyl cellulose), polyethylene glycols (PEG), chitosan, polyesters (e.g., polycaprolactones), and poly(lactic-co-glycolic) acids (e.g., poly(d-lactic-co-glycolic) acids). The coating can include therapeutic agent or can be substantially free of therapeutic agent. The therapeutic agent in the coating can be the same as or different from an agent on a surface layer of the particle. A polymer coating, e.g. an erodible coating, can be applied to the particle surface in cases in which a high concentration of therapeutic agent has not been applied to the particle surface. Coatings are described, for example, in U.S. patent application Ser. No. 10/615,276, filed on Jul. 8, 2003, and entitled “Agent Delivery Particle”, which is incorporated herein by reference.


As an additional example, in some embodiments one or more particles is/are substantially nonspherical. In some embodiments, particles can be shaped (e.g., molded, compressed, punched, and/or agglomerated with other particles) at different points in the particle manufacturing process. Shaped particles are described, for example, in Bourne et al., U.S. Published Patent Application No. US 2003/0203985 A1, which is incorporated herein by reference.


As a further example, in some embodiments the particles can be used for tissue bulking. As an example, the particles can be placed (e.g., injected) into tissue adjacent to a body passageway. The particles can narrow the passageway, thereby providing bulk and allowing the tissue to constrict the passageway more easily. The particles can be placed in the tissue according to a number of different methods, for example, percutaneously, laparoscopically, and/or through a catheter. In certain embodiments, a cavity can be formed in the tissue, and the particles can be placed in the cavity. Particle tissue bulking can be used to treat, for example, intrinsic sphincteric deficiency (ISD), vesicoureteral reflux, gastroesophageal reflux disease (GERD), and/or vocal cord paralysis (e.g., to restore glottic competence in cases of paralytic dysphonia). In some embodiments, particle tissue bulking can be used to treat urinary incontinence and/or fecal incontinence. The particles can be used as a graft material or a filler to fill and/or to smooth out soft tissue defects, such as for reconstructive or cosmetic applications (e.g., surgery). Examples of soft tissue defect applications include cleft lips, scars (e.g., depressed scars from chicken pox or acne scars), indentations resulting from liposuction, wrinkles (e.g., glabella frown wrinkles), and soft tissue augmentation of thin lips. Tissue bulking is described, for example, in Bourne et al., U.S. Published Patent Application No. US 2003/0233150 A1, which is incorporated herein by reference.


As another example, the particles can include (e.g., encapsulate) diagnostic agent(s) such as a radiopaque material, an MRI-visible material, a ferromagnetic material, and/or an ultrasound contrast agent. For example, a silica particle can encapsulate a ferromagnetic material so that the position of the particle in a lumen can be manipulated with a magnetic field. The magnetic field can be created outside the subject or inside the subject (e.g., via a magnetic catheter). In some embodiments, a ferromagnetic material can be incorporated into silica particles by adding the magnetic material to the silica hydrosol mix (step 300, FIG. 3) and forming particles as illustrated in FIG. 3. Particles containing diagnostic agents are described in U.S. patent application Ser. No. 10/651,475, filed on Aug. 29, 2003, and entitled “Embolization”, and magnetic devices are described in U.S. patent application Ser. No. 10/108,874, filed on Mar. 29, 2002, and entitled “Magnetically Enhanced Injection Catheter”, both of which are incorporated herein by reference.


As yet another example, in certain embodiments, a particle can include one or more therapeutic agents (e.g., in the pores of the particle) and one or more diagnostic agents (e.g., one or more ferromagnetic materials encapsulated in the silica). In certain embodiments, a therapeutic agent can be conjugated with a diagnostic agent. Including both therapeutic agent(s) and diagnostic agent(s) in a particle can enhance the ability to deliver the therapeutic agent in a targeted way.


As a further example, in some embodiments a particle contains materials in addition to silica. For example, in some embodiments, the particle can include one or more polymeric materials (e.g., matrix polymeric materials). Examples of polymeric materials include polyvinyl alcohols, polyacrylic acids, polymethacrylic acids, poly vinyl sulfonates, carboxymethyl celluloses, hydroxyethyl celluloses, substituted celluloses, polyacrylamides, polyethylene glycols, polyamides, polyureas, polyurethanes, polyesters, polyethers, polystyrenes, polysaccharides, polylactic acids, polyethylenes, polymethylmethacrylates, polycaprolactones, polyglycolic acids, poly(lactic-co-glycolic) acids (e.g., poly(d-lactic-co-glycolic) acids), and copolymers or mixtures thereof. In some embodiments, the polymer can be substantially formed of a highly water insoluble, high molecular weight polymer. An example of such a polymer is a high molecular weight polyvinyl alcohol (PVA) that has been acetalized. A polymer can be substantially pure intrachain 1,3-acetalized PVA and substantially free of animal derived residue such as collagen. Examples of particles containing such materials are disclosed in U.S. patent application Ser. No. 10/637,130, filed Aug. 8, 2003, and entitled “Embolization”, which is hereby incorporated by reference.


As an additional example, in some embodiments, a particle can be shaped, such as described, for example, in U.S. patent application Ser. No. 10/700,970, filed on Nov. 4, 2003, and entitled “Embolization”, and U.S. patent application Ser. No. 10/700,403 filed on Nov. 4, 2003, and entitled “Embolization”, both of which are incorporated herein by reference.


As another example, in some embodiments a particle can be formed with no pores and/or no cavities.


Other embodiments are in the claims.

Claims
  • 1. A composition, comprising: a plurality of substantially spherical porous silica particles, at least some of the plurality of substantially spherical silica particles having a diameter of from about 100 microns to about 3000 microns; anda carrier fluid, the plurality of substantially spherical porous particles being in the carrier fluid,wherein: for at least some of the plurality of substantially spherical porous silica particles, a pore volume of the substantially spherical porous silica particles is from about 0.4 ml/g to about 1.6 ml/g; andthe plurality of substantially spherical porous silica particles have a pore volume distribution such that about 70% or more of the pore volume of the plurality of substantially spherical porous silica particles is made up of pores having pore diameters which have a tolerance of about 10 nm or less on the mean pore diameter.
  • 2. The composition of claim 1, wherein the carrier fluid comprises a saline solution.
  • 3. The composition of claim 1, wherein the carrier fluid comprises a contrast agent.
  • 4. The composition of claim 1, wherein at least some of the plurality of substantially spherical porous silica particles have a diameter of at most about 1500 microns.
  • 5. The composition of claim 1, wherein, for at least some of the plurality of substantially spherical porous silica particles, pores in the substantially spherical porous silica particles have a diameter of from about 20 nanometers to about 90 nanometers.
  • 6. The composition of claim 1, wherein, for at least some of the plurality of substantially spherical porous silica particles, the density of the particles is from about 1.1 grams per cubic centimeter to about 1.4 grams per cubic centimeter.
  • 7. The composition of claim 1, wherein the substantially spherical porous silica particles exhibit a loss of attrition resistance of about 0.1% by weight or less.
  • 8. The composition of claim 1, wherein at least some of the plurality of substantially spherical porous silica particles include a material selected from the group consisting of therapeutic agents, ferromagnetic materials, MRI visible materials and radiopaque materials.
  • 9. The composition of claim 1, wherein the plurality of substantially spherical porous silica particles are sterilized.
  • 10. A composition, comprising: a plurality of substantially spherical porous silica particles, at least some of the plurality of substantially spherical silica particles having a diameter of from about 100 microns to about 3000 microns; anda carrier fluid, the plurality of substantially spherical porous particles being in the carrier fluid,wherein, for at least some of the plurality of substantially spherical porous silica particles, the density of the particles is from about 1.1 grams per cubic centimeter to about 1.4 grams per cubic centimeter, and the carrier fluid comprises a saline solution, wherein the plurality of substantially spherical porous silica particles have a pore volume distribution such that about 70% or more of the pore volume of the plurality of substantially spherical porous silica particles is made up of pores having pore diameters which have a tolerance of about 10 nm or less on the mean pore diameter.
  • 11. The composition of claim 10, wherein the substantially spherical porous silica particles exhibit a loss of attrition resistance of about 0.1% by weight or less.
  • 12. A composition, comprising: a plurality of substantially spherical porous silica particles, at least some of the plurality of substantially spherical silica particles having a diameter of from about 100 microns to about 3000 microns; anda carrier fluid, the plurality of substantially spherical porous particles being in the carrier fluid,wherein the plurality of substantially spherical porous silica particles have a pore volume distribution such that about 70% or more of the pore volume of the plurality of substantially spherical porous silica particles is made up of pores having pore diameters which have a tolerance of about 10 nm or less on the mean pore diameter.
  • 13. The composition of claim 12, wherein the substantially spherical porous silica particles exhibit a loss of attrition resistance of about 0.1% by weight or less.
US Referenced Citations (343)
Number Name Date Kind
2275154 Merrill et al. Mar 1942 A
2609347 Wilson Sep 1952 A
3663470 Nishimura et al. May 1972 A
3737398 Yamaguchi Jun 1973 A
3957933 Egli et al. May 1976 A
4025686 Zion May 1977 A
4034759 Haerr Jul 1977 A
4055377 Erickson et al. Oct 1977 A
4076640 Forgensi et al. Feb 1978 A
4094848 Naito Jun 1978 A
4096230 Haerr Jun 1978 A
4098728 Rosenblatt Jul 1978 A
4110529 Stoy Aug 1978 A
4159719 Haerr Jul 1979 A
4191672 Salome et al. Mar 1980 A
4198318 Stowell et al. Apr 1980 A
4243794 White et al. Jan 1981 A
4246208 Dundas Jan 1981 A
4266030 Tschang et al. May 1981 A
4268495 Muxfeldt et al. May 1981 A
4271281 Kelley et al. Jun 1981 A
4402319 Handa et al. Sep 1983 A
4413070 Rembaum Nov 1983 A
4427794 Lange et al. Jan 1984 A
4428869 Munteanu et al. Jan 1984 A
4429062 Pasztor et al. Jan 1984 A
4442843 Rasor et al. Apr 1984 A
4444961 Timm Apr 1984 A
4452773 Molday Jun 1984 A
4456693 Welsh Jun 1984 A
4459145 Elsholz Jul 1984 A
4472552 Blouin Sep 1984 A
4477255 Pasztor et al. Oct 1984 A
4492720 Moiser Jan 1985 A
4515906 Friesen et al. May 1985 A
4522953 Barby et al. Jun 1985 A
4542178 Zimmermann et al. Sep 1985 A
4551132 Pasztor et al. Nov 1985 A
4551436 Johnson et al. Nov 1985 A
4573967 Hargrove et al. Mar 1986 A
4622362 Rembaum Nov 1986 A
4623706 Timm et al. Nov 1986 A
4640807 Afghan et al. Feb 1987 A
4657756 Rasor et al. Apr 1987 A
4661137 Garnier et al. Apr 1987 A
4663358 Hyon et al. May 1987 A
4671954 Goldberg et al. Jun 1987 A
4674480 Lemelson Jun 1987 A
4675113 Graves et al. Jun 1987 A
4678710 Sakimoto et al. Jul 1987 A
4678814 Rembaum Jul 1987 A
4680320 Uku et al. Jul 1987 A
4681119 Rasor et al. Jul 1987 A
4695466 Morishita et al. Sep 1987 A
4713076 Draenert Dec 1987 A
4742086 Masamizu et al. May 1988 A
4743507 Franses et al. May 1988 A
4772635 Mitschker et al. Sep 1988 A
4782097 Jain et al. Nov 1988 A
4789501 Day et al. Dec 1988 A
4793980 Torobin Dec 1988 A
4795741 Leshchiner et al. Jan 1989 A
4801458 Hidaka et al. Jan 1989 A
4804366 Zdeb et al. Feb 1989 A
4819637 Dormandy, Jr. et al. Apr 1989 A
4822535 Ekman et al. Apr 1989 A
4833237 Kawamura et al. May 1989 A
4850978 Dudar et al. Jul 1989 A
4859711 Jain et al. Aug 1989 A
4863972 Itagaki et al. Sep 1989 A
4897255 Fritzberg et al. Jan 1990 A
4929400 Rembaum et al. May 1990 A
4933372 Feibush et al. Jun 1990 A
4946899 Kennedy et al. Aug 1990 A
4954399 Tani et al. Sep 1990 A
4981625 Rhim et al. Jan 1991 A
4990340 Hidaka et al. Feb 1991 A
4999188 Sololdovnik et al. Mar 1991 A
5007940 Berg Apr 1991 A
5011677 Day et al. Apr 1991 A
H915 Gibbs May 1991 H
5015423 Eguchi et al. May 1991 A
5032117 Motta Jul 1991 A
5034324 Shinozaki et al. Jul 1991 A
5047438 Feibush et al. Sep 1991 A
5079274 Schneider et al. Jan 1992 A
5091205 Fan Feb 1992 A
5106903 Vanderhoff et al. Apr 1992 A
5114421 Polak May 1992 A
5116387 Berg May 1992 A
5120349 Stewart et al. Jun 1992 A
5125892 Drudik Jun 1992 A
5147631 Glajch et al. Sep 1992 A
5147937 Frazza et al. Sep 1992 A
5149543 Cohen et al. Sep 1992 A
5158573 Berg Oct 1992 A
5171214 Kolber et al. Dec 1992 A
5171217 March et al. Dec 1992 A
5181921 Makita et al. Jan 1993 A
5190760 Baker Mar 1993 A
5190766 Ishihara Mar 1993 A
5192301 Kamiya et al. Mar 1993 A
5202352 Okada et al. Apr 1993 A
5216096 Hattori et al. Jun 1993 A
5253991 Yokota et al. Oct 1993 A
5260002 Wang Nov 1993 A
5262176 Palmacci et al. Nov 1993 A
5263992 Guire Nov 1993 A
5288763 Li et al. Feb 1994 A
5292814 Bayer et al. Mar 1994 A
5302369 Day et al. Apr 1994 A
5314974 Ito et al. May 1994 A
5316774 Eury et al. May 1994 A
RE34640 Kennedy et al. Jun 1994 E
5320639 Rudnick Jun 1994 A
5328936 Leifholtz et al. Jul 1994 A
5336263 Ersek et al. Aug 1994 A
5344452 Lemperle Sep 1994 A
5344867 Morgan et al. Sep 1994 A
5354290 Gross Oct 1994 A
5369133 Ihm et al. Nov 1994 A
5369163 Chiou et al. Nov 1994 A
5382260 Dormandy, Jr. et al. Jan 1995 A
5384124 Courteille et al. Jan 1995 A
5397303 Sancoff et al. Mar 1995 A
5398851 Sancoff et al. Mar 1995 A
5403870 Gross Apr 1995 A
5417982 Modi May 1995 A
5431174 Knute Jul 1995 A
5435645 Faccioli et al. Jul 1995 A
5443495 Buscemi et al. Aug 1995 A
5456693 Conston et al. Oct 1995 A
5468801 Antonelli et al. Nov 1995 A
5469854 Unger et al. Nov 1995 A
5476472 Dormandy, Jr. et al. Dec 1995 A
5484584 Wallace et al. Jan 1996 A
5490984 Freed Feb 1996 A
5494682 Cohen et al. Feb 1996 A
5494940 Unger et al. Feb 1996 A
5512604 Demopolis Apr 1996 A
5514090 Kriesel et al. May 1996 A
5514347 Ohashi et al. May 1996 A
5525334 Ito et al. Jun 1996 A
5534589 Hager et al. Jul 1996 A
5541031 Yamashita et al. Jul 1996 A
5542935 Unger et al. Aug 1996 A
5553741 Sancoff et al. Sep 1996 A
5556391 Cercone et al. Sep 1996 A
5556610 Yan et al. Sep 1996 A
5558255 Sancoff et al. Sep 1996 A
5558822 Gitman et al. Sep 1996 A
5558856 Klaveness et al. Sep 1996 A
5559266 Klaveness et al. Sep 1996 A
5567415 Porter Oct 1996 A
5569193 Hofstetter et al. Oct 1996 A
5569449 Klaveness et al. Oct 1996 A
5569468 Modi Oct 1996 A
5571182 Ersek et al. Nov 1996 A
5580575 Unger et al. Dec 1996 A
5583162 Li et al. Dec 1996 A
5585112 Unger et al. Dec 1996 A
5595821 Hager et al. Jan 1997 A
5622657 Takada et al. Apr 1997 A
5624685 Takahashi et al. Apr 1997 A
5635215 Boschetti et al. Jun 1997 A
5637087 O'Neil et al. Jun 1997 A
5639710 Lo et al. Jun 1997 A
5648095 Illum et al. Jul 1997 A
5648100 Boschetti et al. Jul 1997 A
5650116 Thompson Jul 1997 A
5651990 Takada et al. Jul 1997 A
5653922 Li et al. Aug 1997 A
5657756 Vrba Aug 1997 A
5681576 Henry Oct 1997 A
5695480 Evans et al. Dec 1997 A
5695740 Porter Dec 1997 A
5698271 Liberti et al. Dec 1997 A
5701899 Porter Dec 1997 A
5715824 Unger et al. Feb 1998 A
5716981 Hunter et al. Feb 1998 A
5718884 Klaveness et al. Feb 1998 A
5723269 Akagi et al. Mar 1998 A
5725534 Rasmussen Mar 1998 A
5733925 Kunz et al. Mar 1998 A
5741331 Pinchuk Apr 1998 A
5746734 Dormandy, Jr. et al. May 1998 A
5752974 Rhee et al. May 1998 A
5756127 Grisoni et al. May 1998 A
5760097 Li et al. Jun 1998 A
5766147 Sancoff et al. Jun 1998 A
5770222 Unger et al. Jun 1998 A
5779668 Grabenkort Jul 1998 A
5785642 Wallace et al. Jul 1998 A
5785682 Grabenkort Jul 1998 A
5792478 Lawin et al. Aug 1998 A
5795562 Klaveness et al. Aug 1998 A
5797953 Tekulve Aug 1998 A
5807323 Kriesel et al. Sep 1998 A
5813411 Van Bladel et al. Sep 1998 A
5823198 Jones et al. Oct 1998 A
5827502 Klaveness et al. Oct 1998 A
5827531 Morrison et al. Oct 1998 A
5830178 Jones et al. Nov 1998 A
5833361 Funk Nov 1998 A
5840387 Berlowitz-Tarrant et al. Nov 1998 A
5846518 Yan et al. Dec 1998 A
5853752 Unger et al. Dec 1998 A
5855615 Bley et al. Jan 1999 A
5863957 Li et al. Jan 1999 A
5876372 Grabenkort et al. Mar 1999 A
5877224 Brocchini et al. Mar 1999 A
5885216 Evans, III et al. Mar 1999 A
5885547 Gray Mar 1999 A
5888546 Ji et al. Mar 1999 A
5888930 Smith et al. Mar 1999 A
5891155 Irie Apr 1999 A
5894022 Ji et al. Apr 1999 A
5895398 Wensel et al. Apr 1999 A
5895411 Irie Apr 1999 A
5899877 Leibitzki et al. May 1999 A
5902832 Van Bladel et al. May 1999 A
5902834 Porrvik May 1999 A
5922025 Hubbard Jul 1999 A
5922304 Unger Jul 1999 A
5928626 Klaveness et al. Jul 1999 A
5935553 Unger et al. Aug 1999 A
5951160 Ronk Sep 1999 A
5957848 Sutton et al. Sep 1999 A
5959073 Schlameus et al. Sep 1999 A
6003566 Thibault et al. Dec 1999 A
6015546 Sutton et al. Jan 2000 A
6027472 Kriesel et al. Feb 2000 A
6028066 Unger Feb 2000 A
6047861 Vidal et al. Apr 2000 A
6048908 Kitagawa Apr 2000 A
6051247 Hench et al. Apr 2000 A
6056721 Shulze May 2000 A
6056844 Guiles et al. May 2000 A
6059766 Greff May 2000 A
6063068 Fowles et al. May 2000 A
6071495 Unger et al. Jun 2000 A
6071497 Steiner et al. Jun 2000 A
6073759 Lamborne et al. Jun 2000 A
6090925 Woiszwillo et al. Jul 2000 A
6096344 Liu et al. Aug 2000 A
6099064 Lund Aug 2000 A
6099864 Morrison et al. Aug 2000 A
6100306 Li et al. Aug 2000 A
6139963 Fujii et al. Oct 2000 A
6149623 Reynolds Nov 2000 A
6160084 Langer et al. Dec 2000 A
6162377 Ghosh et al. Dec 2000 A
6165193 Greene, Jr. et al. Dec 2000 A
6179817 Zhong Jan 2001 B1
6191193 Lee et al. Feb 2001 B1
6214331 Vanderhoff et al. Apr 2001 B1
6214384 Pallado et al. Apr 2001 B1
6224630 Bao et al. May 2001 B1
6224794 Amsden et al. May 2001 B1
6235224 Mathiowitz et al. May 2001 B1
6238403 Greene, Jr. et al. May 2001 B1
6245090 Gilson et al. Jun 2001 B1
6251661 Urabe et al. Jun 2001 B1
6258338 Gray Jul 2001 B1
6261585 Sefton et al. Jul 2001 B1
6264861 Tavernier et al. Jul 2001 B1
6267154 Felicelli et al. Jul 2001 B1
6268053 Woiszwillo et al. Jul 2001 B1
6277392 Klein Aug 2001 B1
6280457 Wallace et al. Aug 2001 B1
6291605 Freeman et al. Sep 2001 B1
6296604 Garibaldi et al. Oct 2001 B1
6296622 Kurz et al. Oct 2001 B1
6296632 Luscher et al. Oct 2001 B1
6306418 Bley Oct 2001 B1
6306419 Vachon et al. Oct 2001 B1
6306425 Tice et al. Oct 2001 B1
6306427 Annonier et al. Oct 2001 B1
6312407 Zadno-Azizi et al. Nov 2001 B1
6312942 Plüss-Wenzinger et al. Nov 2001 B1
6315709 Garibaldi et al. Nov 2001 B1
6335384 Evans et al. Jan 2002 B1
6344182 Sutton et al. Feb 2002 B1
6355275 Klein Mar 2002 B1
6368658 Schwarz et al. Apr 2002 B1
6379373 Sawhney et al. Apr 2002 B1
6388043 Langer et al. May 2002 B1
6394965 Klein May 2002 B1
6423332 Huxel et al. Jul 2002 B1
6432437 Hubbard Aug 2002 B1
6436112 Wensel et al. Aug 2002 B2
6443941 Slepian et al. Sep 2002 B1
6458296 Heinzen et al. Oct 2002 B1
6468493 Chevallier et al. Oct 2002 B1
6476069 Krall et al. Nov 2002 B2
6482324 Kirkland et al. Nov 2002 B2
6495155 Tice et al. Dec 2002 B1
6544503 Vanderhoff et al. Apr 2003 B1
6544544 Hunter et al. Apr 2003 B2
6545097 Pinchuk et al. Apr 2003 B2
6575896 Silverman et al. Jun 2003 B2
6602261 Greene, Jr. et al. Aug 2003 B2
6602524 Batich et al. Aug 2003 B2
6605111 Bose et al. Aug 2003 B2
6629947 Sahatjian et al. Oct 2003 B1
6632531 Blankenship Oct 2003 B2
6652883 Goupil et al. Nov 2003 B2
6680046 Boschetti Jan 2004 B1
6699222 Jones et al. Mar 2004 B1
7591993 Boschetti Sep 2009 B2
20010001835 Greene, Jr. et al. May 2001 A1
20010016210 Mathiowitz et al. Aug 2001 A1
20010036451 Goupil et al. Nov 2001 A1
20010051670 Goupil et al. Dec 2001 A1
20020054912 Kim et al. May 2002 A1
20020061954 Davis et al. May 2002 A1
20020160109 Yeo et al. Oct 2002 A1
20020182190 Naimark et al. Dec 2002 A1
20020197208 Ruys et al. Dec 2002 A1
20030007928 Gray Jan 2003 A1
20030032935 Damiano et al. Feb 2003 A1
20030108614 Volkonsky et al. Jun 2003 A1
20030183962 Buiser et al. Oct 2003 A1
20030185895 Lanphere et al. Oct 2003 A1
20030185896 Buiser et al. Oct 2003 A1
20030187320 Freyman Oct 2003 A1
20030194390 Krall et al. Oct 2003 A1
20030203985 Baldwin et al. Oct 2003 A1
20030206864 Mangin Nov 2003 A1
20030215519 Schwarz et al. Nov 2003 A1
20030233150 Bourne et al. Dec 2003 A1
20040076582 DiMatteo et al. Apr 2004 A1
20040091543 Bell et al. May 2004 A1
20040092883 Casey, III et al. May 2004 A1
20040096662 Lanphere et al. May 2004 A1
20040101564 Rioux et al. May 2004 A1
20040186377 Zhong et al. Sep 2004 A1
20050025800 Tan Feb 2005 A1
20050037047 Song Feb 2005 A1
20050048859 Canham et al. Mar 2005 A1
20050095428 DiCarlo et al. May 2005 A1
20050129775 Lanphere et al. Jun 2005 A1
20050196449 Dicarlo et al. Sep 2005 A1
Foreign Referenced Citations (84)
Number Date Country
A-7618698 Oct 1998 AU
3834705 Apr 1990 DE
94 14 868.6 Feb 1995 DE
297 24 255 Oct 2000 DE
100 26 620 A 1 Mar 2002 DE
0067459 Dec 1982 EP
0 122 624 Oct 1984 EP
0 123 235 Oct 1984 EP
0243165 Oct 1987 EP
0294206 Dec 1988 EP
0 422 258 Oct 1989 EP
0 402 031 May 1990 EP
0 458 079 Nov 1991 EP
0 458 745 Nov 1991 EP
0 470 569 Feb 1992 EP
0 547 530 Jun 1993 EP
0 600 529 Dec 1993 EP
0 623 012 Nov 1994 EP
0 706 376 Apr 1996 EP
0 730 847 Sep 1996 EP
0 744 940 Dec 1996 EP
0 797 988 Oct 1997 EP
0 067 459 Mar 1998 EP
0 764 047 Aug 2003 EP
0 993 337 Apr 2004 EP
2 096 521 Mar 1997 ES
59-196738 Nov 1984 JP
62-45637 Feb 1987 JP
4-74117 Mar 1992 JP
6-57012 Mar 1994 JP
9-110678 Apr 1997 JP
9-165328 Jun 1997 JP
9-316271 Dec 1997 JP
10-130329 May 1998 JP
2000189511 Jul 2000 JP
2001079011 Mar 2001 JP
2002 017848 Jan 2002 JP
255409 Feb 1997 NZ
517377 Aug 2003 NZ
421658 Feb 2001 TW
WO 9112823 May 1991 WO
WO 9221327 Dec 1992 WO
WO 9300063 Jan 1993 WO
WO 9319702 Oct 1993 WO
WO 9410936 May 1994 WO
WO 9503036 Feb 1995 WO
WO 9522318 Aug 1995 WO
WO 9533553 Dec 1995 WO
WO 9637165 Nov 1996 WO
WO 9639464 Dec 1996 WO
WO 9804616 Feb 1998 WO
WO 9810798 Mar 1998 WO
WO 9826737 Jun 1998 WO
WO 9847532 Oct 1998 WO
WO 9900187 Jan 1999 WO
WO 9912577 Mar 1999 WO
WO 9943380 Sep 1999 WO
WO 9951278 Oct 1999 WO
WO 9957176 Nov 1999 WO
WO 0023054 Apr 2000 WO
WO 0032112 Jun 2000 WO
WO 0040259 Jul 2000 WO
WO 0071196 Nov 2000 WO
WO0066183 Nov 2000 WO
WO 0074633 Dec 2000 WO
WO 0112359 Feb 2001 WO
WO 0166016 Sep 2001 WO
WO 0170291 Sep 2001 WO
WO 0172281 Oct 2001 WO
WO 0176845 Oct 2001 WO
WO 0193920 Dec 2001 WO
WO 0211696 Feb 2002 WO
WO 0234298 May 2002 WO
WO 0234299 May 2002 WO
WO 0234300 May 2002 WO
WO 0243580 Jun 2002 WO
WO 03013552 Feb 2003 WO
WO03016364 Feb 2003 WO
WO 03051451 Jun 2003 WO
WO03082359 Sep 2003 WO
WO2004019999 Mar 2004 WO
WO 2004040972 May 2004 WO
WO 2004073688 Sep 2004 WO
WO2004075989 Sep 2004 WO
Related Publications (1)
Number Date Country
20050226935 A1 Oct 2005 US